Atara Biotherapeutics

Atara Biotherapeutics is a leading allogeneic T-cell immunotherapy company pioneering off-the-shelf treatments for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Atara's platform leverages the unique biology of EBV T cells and can treat a wide range of EBV-associated diseases or other serious conditions through incorporation of engineered CARs or TCRs — without requiring TCR or HLA gene editing. The company's lead program, tabelecleucel (tab-cel), has received marketing authorization in Europe for EBV+ post-transplant lymphoproliferative disease (PTLD). Atara is publicly traded on Nasdaq (ATRA) and is headquartered in Thousand Oaks, California.